This is what the news should sound like. The biggest stories of our time, told by the best journalists in the world. Hosted by Michael Barbaro. Twenty minutes a day, five days a week, ready by 6 a.m. Unlock full access to New York Times podcasts and explore everything from politics to pop culture. Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. Listen to this podcast in New York Times Audio, our new iOS app for news subscribers. Download now at nytimes.com/audioapp
…
continue reading
Content provided by Audioboom and Not So Different: a Podcast from The Center for Biosimilars. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Not So Different: a Podcast from The Center for Biosimilars or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
S6 Ep29: Biosimilars Policy Roundup for April 2024—Podcast Edition
MP3•Episode home
Manage episode 416565834 series 2161808
Content provided by Audioboom and Not So Different: a Podcast from The Center for Biosimilars. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Not So Different: a Podcast from The Center for Biosimilars or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Show notes
FDA Approves Henlius’ Trastuzumab Biosimilar, Hercessi
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
AON Saves Over $243 Million With High Biosimilar Adoption
Julie Reed: Why 2024 Is Important for Biosimilars
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
AON Saves Over $243 Million With High Biosimilar Adoption
Julie Reed: Why 2024 Is Important for Biosimilars
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
155 episodes
MP3•Episode home
Manage episode 416565834 series 2161808
Content provided by Audioboom and Not So Different: a Podcast from The Center for Biosimilars. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Not So Different: a Podcast from The Center for Biosimilars or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Show notes
FDA Approves Henlius’ Trastuzumab Biosimilar, Hercessi
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
AON Saves Over $243 Million With High Biosimilar Adoption
Julie Reed: Why 2024 Is Important for Biosimilars
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
AON Saves Over $243 Million With High Biosimilar Adoption
Julie Reed: Why 2024 Is Important for Biosimilars
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
155 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.